

# Supplementary material: Quarantine and testing strategies for safe pandemic travel

Chad R. Wells<sup>1</sup>, Jeffrey P. Townsend<sup>2,3,4,5\*</sup>, Abhishek Pandey<sup>1</sup>, Meagan C. Fitzpatrick<sup>1,6</sup>, William S. Crystal<sup>7</sup>, Seyed M. Moghadas,<sup>8</sup> Alison P. Galvani<sup>1,3</sup>

<sup>1</sup>Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut 06520, USA

<sup>2</sup>Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut 06510, USA

<sup>3</sup>Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut 06525, USA

<sup>4</sup>Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut 06511, USA

<sup>5</sup>Program in Microbiology, Yale University, New Haven, Connecticut 06511, USA

<sup>6</sup>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, 21201, USA

<sup>7</sup>Yale College, New Haven, CT 06520

<sup>8</sup>Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada

These authors contributed equally: Chad R. Wells and Jeffrey P. Townsend

\*Corresponding author: Jeffrey.Townsend@Yale.edu

## Supplementary methods

### Long-term travel quarantine

*With no travel.* Country-specific imminent infection in country A with no travel from country B to country A is

$N_T c_A R_A (1 - \varphi_A)$ , where  $N_T$  is the total population of country A,  $c_A$  is the fractional incidence per day within country A,

$R_A$  is the effective reproduction number including non-immunological public health measures, and  $\varphi_A$  is the percent of

country A that is immune. The term  $\varphi_A$  can be decomposed into the fraction who are currently infected plus the fraction

that have either recovered from infection and remain immune or have been vaccinated and remain immune.

*With only long-term travel to country B and return to country A.* Country-specific imminent infection in country A with

long-term travel is composed of non-travelers and travelers. The daily contribution to imminent infection of non-travelers

is  $N_A c_A R_A (1 - \varphi_A)$ , where  $N_A$  is the number of non-traveling and non-quarantined country-A residents. At steady-state,

the daily contribution to imminent infection of returning travelers is  $n_{A,B} \rho_B R_{Q_A, V} (1 - \varphi_A)$ , where  $n_{A,B}$  is the daily number of country-A residents returning from a long-term visit to country B,  $\rho_B$  is the prevalence of non-isolated infections in country B, and  $R_{Q_A, V}$  is the average ‘left-over’ imminent infection in country A of an infected visitor who underwent the quarantine-and-testing regime  $Q_A$ . Simultaneously, the departure of infected individuals decreases imminent infection by  $n_{A,B} \rho_A R_V (1 - \varphi_A)$ , where  $R_V$  is the average ‘left-over’ imminent infection of an infected visitor to country A leaving at an unknown time in their infection period. The details of computing  $R_V$  and  $R_{Q_A, V}$  are described later in Supplementary Materials. Therefore, permitting the population in country A to perform long-term travel to and return from country B is no worse than border closure in terms of daily imminent infection when

$$N_T c_A R_A (1 - \varphi_A) \geq N_A c_A R_A (1 - \varphi_A) - n_{A,B} \rho_A R_V (1 - \varphi_A) + n_{A,B} \rho_B R_{Q_A, V} (1 - \varphi_A). \quad (1)$$

*A sufficient quarantine to ameliorate transmission in country A from long-term travel to country B and return to country A, and long-term travel to country A from country B.* Country-specific imminent infection in country A with long-term travel is also increased by travelers from country B, whose contribution is  $n_{B,A} \rho_B R_{Q_A, V} (1 - \varphi_A)$ , where  $n_{B,A}$  is the daily number of long-term visitors from country B to country A. Country-specific imminent infection in country A with long-term travel is also increased by travelers from country B infected in country A, whose contribution is  $n_B c_A \left( \frac{1 - \varphi_B}{1 - \varphi_A} \right) R_A (1 - \varphi_A)$ , where  $n_B$  is number of residents of country B abroad in country A, and  $\frac{1 - \varphi_B}{1 - \varphi_A}$  is the infection risk ratio for individuals who are not immune to infection at frequency  $1 - \varphi_B$  while in country A with its frequency of susceptibility  $1 - \varphi_A$ . Simultaneously, the departure of infected individuals from country B decreases imminent infection by  $n_{B,A} \rho_A \left( \frac{1 - \varphi_B}{1 - \varphi_A} \right) R_V (1 - \varphi_A)$ . Therefore, permitting the population in country A to perform long-term travel to and return from country B, as well as permitting long-term travel from country B to country A, is no worse than border closure in terms of daily imminent infection when

$$N_T c_A R_A (1 - \varphi_A) \geq$$

$$N_A c_A R_A (1 - \varphi_A) + n_B c_A \left( \frac{1 - \varphi_B}{1 - \varphi_A} \right) R_A (1 - \varphi_A) \quad (2)$$

$$- n_{A,B} \rho_A R_V (1 - \varphi_A) + n_{A,B} \rho_B \left( \frac{1 - \varphi_A}{1 - \varphi_B} \right) R_{Q_A, V} (1 - \varphi_A) + n_{B,A} \rho_B R_{Q_A, V} (1 - \varphi_A) - n_{B,A} \rho_A \left( \frac{1 - \varphi_B}{1 - \varphi_A} \right) R_V (1 - \varphi_A) .$$

Countries may wish to impose the least onerous quarantine-and-testing approach  $Q_A$  that satisfies this condition.

We summarize the terms of the inequality for the imminent infections (Eq. 2) using indexed symbols (**Table S4**).

Specifically, we simplify the different terms of the expressions to reflect age-dependent disease characteristics using  $\lambda_{k,j}$  to denote the  $k^{\text{th}}$  term for age class  $j$  (**Table S4**). Accounting for age-dependent disease characteristics, we can specify the inequality as

$$\sum_{j=1}^X (1 - \varphi_A) \lambda_{0j} \geq \sum_{j=1}^N (1 - \varphi_A) (\lambda_{1j} + \lambda_{2j} - \lambda_{3j} + \lambda_{4j} + \lambda_{5j} - \lambda_{6j}).$$

Specifying that  $\theta_{k,i}$  proportion of infections are of variant  $k$  in country  $i$ , portion of the entire population immune to the

infection  $\varphi_{i,k} = \sum_{j=1}^A w_{i,j} \varphi_{i,k,j}$ , increasing transmission by factor  $\tau_k$ , the inequalities determining the number of imminent

infections in or destination country  $i$  when interacting with origin country  $m$  is

$$\sum_{j=1}^A (1 + \tau_k) (1 - \varphi_{k,i}) \theta_{k,i} \lambda_{0j} \geq \sum_{j=1}^A (1 + \tau_k) (1 - \varphi_{k,i}) \left( \theta_{k,i} \lambda_{1j} + \theta_{k,i} \lambda_{2j} - \theta_{k,i} \lambda_{3j} + \theta_{k,m} \lambda_{4j} + \theta_{k,m} \lambda_{5j} - \theta_{k,i} \lambda_{6j} \right) \forall k.$$

Specifically, the minimum travel quarantine travel duration is the period in which all inequalities for the variants of interest are satisfied (i.e. the maximum of all the minimum travel quarantine durations). For our analysis on the variants of concern, we evaluate B.1.1.7, B.1.351, and generalized transmission by non-B.1.1.7 non-B.1.351 strains. In this analysis, we specify the proportion of infections of from general transmission to be  $\theta_{1,i} = 1 - \theta_{2,i} - \theta_{3,i}$ .

### Variants of concern

Our analytical approach can naturally incorporate variants of concern as independent factors to control. To demonstrate this flexibility, we incorporated two known variants of concern, B.1.1.7 and B.1.351, in an additional analysis. We consider increased transmission of the VOC relative to general transmission, 100% cross-immunity, and no reduction in vaccine efficacy. The B.1.1.7 VOC has been estimated to be up to 82% more infectious than previous strains [1–3], where B.1.351 has been estimated to be 50% more transmissible [3]. Current studies have highlighted reduction in neutralization for the VOC in regards to immunity, but it is not clear how much this reduced neutralization translates to reduction in the efficacy of the vaccine. These components can be integrated as more information about immunity and VOC appear. The assumption of 100% cross immunity also pertains to limited information of the proportion of the population previously infected with the VOC. We obtained the frequency of these two variants based on genetic surveillance [4]. The accuracy of the frequency of the VOC obtained from the data is limited by the country's frequency of genetic analysis of the samples. When considering multiple variants of concern, the sufficient duration of travel quarantine was defined as the duration that satisfies the imminent infection inequality for all variants considered.

### Effective reproduction number

A proportion of infections  $p_A$  will remain asymptomatic over the entire disease time course  $t_E$ , where  $1 - p_A$  infections will develop symptoms  $t_S$  days post-infection. Once an individual exhibits symptoms, they are assumed to self-isolate and to no longer transmit the disease. To indicate the appearance of symptoms post infection, we use a binary step function,

$$H(t) = \begin{cases} 0, & t < t_S, \\ 1, & t \geq t_S \end{cases},$$

where  $f(t)$  is the infectivity over the course of the disease and  $t_E$  is the duration of the disease. We denote the infectivity over time

$$r(t) = \begin{cases} R_0 f(t), & t \leq t_E, \\ 0, & t > t_E, \end{cases}.$$

The average number of secondary infections in the absence of self-isolation is

$$R_0 = \int_0^{\infty} r(t) dt.$$

For an asymptomatic individual, the transmission over time is  $r_A(t) = r(t)$ . To model the isolation of infected individuals for whom symptoms manifest, we denote their transmission over time as  $r_S(t) = r(t) \cdot (1 - H(t))$ .

For a soon-to-be symptomatic case from the time of infection until the time they develop symptoms, we calculate the effective reproduction number

$$R_{Sym} = \int_{t=0}^{\infty} r_S(t) dt = \int_{t=0}^{t_s} r(t) dt.$$

For asymptomatics from the time of infection until the end of the disease time course, we calculate the effective reproduction number

$$R_{Asym} = \int_{t=0}^{\infty} r(t) dt.$$

Thus, the effective reproduction number including non-immunological public health measures in country A is

$$R_A = (1 - p_A) R_{Sym} + p_A R_{Asym}.$$

### Unknown time of infection

#### *Quarantine and testing*

We model individuals as entering quarantine randomly over the period in which they do not exhibit symptoms. The diagnostic sensitivity of a test at time  $t$  is denoted  $s(t)$ . Individuals who are showing symptoms are not eligible for quarantine and instead are placed in isolation. For a specified duration of quarantine ( $q$ ), delay in obtaining test result ( $d$ ) and testing occurring over the course of quarantine ( $t_i$ ), the expected post-quarantine transmission for a soon-to-be symptomatic case is who is tested for disease at any time  $0 \leq t_n \leq q - d_t$  is

$$R_{Sym,Q,V}(q) = \frac{1}{t_s} \int_{u=0}^{t_s} \int_{t=q}^{\infty} r_S(t+u) \cdot \prod_{n=1}^N (1 - s(t_n + u)) dt du.$$

For asymptomatic carriers,

$$R_{Asym,Q,V}(q) = \frac{1}{t_E} \int_{t_E}^{t_E} \int_{u=0}^{\infty} r(t+u) \cdot \prod_{n=1}^N (1 - s(t_n + u)) dt du.$$

Therefore, the expected post-quarantine transmission is

$$R_{Q,V}(q) = (1 - p_A)R_{Sym,Q,V}(q) + p_A R_{Asym,Q,V}(q).$$

Some individuals travelling abroad will be infectious and will no longer contribute to transmission within the country. The remaining amount of transmission for these individuals is analogous to a zero-day quarantine with no test.

The expected remaining transmission for a soon-to-be symptomatic case is

$$R_{Sym,V} = \frac{1}{t_S} \int_{t_S}^{t_S} \int_{u=0}^{\infty} r_S(t+u) dt du.$$

For asymptomatic carriers,

$$R_{Asym,V} = \frac{1}{t_E} \int_{t_E}^{t_E} \int_{u=0}^{\infty} r(t+u) dt du.$$

Therefore, the expected remaining transmission for infected travellers is

$$R_V = (1 - p_A)R_{Sym,V} + p_A R_{Asym,V}.$$

### Temporal diagnostic sensitivity of an RT-PCR test

To determine the diagnostic sensitivity of the RT-PCR assay, we use serial testing data conducted within the healthcare setting [5]. We use a similar methodology as Hellewell et al [5] to infer the diagnostic sensitivity. However, unlike Hellewell et al [5], we specified the diagnostic sensitivity function to be dependent on the infectivity,  $f(t)$ , (a proxy for the viral load) instead of only time. Specifically, the probability the RT-PCR test is positive (i.e. diagnostic sensitivity) at time  $t$  is expressed as

$$s(t) = f(t)^n / (f(t)^n + K),$$

where  $n$  is the Hill coefficient and  $K$  is a saturation constant to be estimated in the fitting.

Data from Hellewell et al [5] specifies whether or not the individual exhibited symptoms on the testing date, the

outcome of the self-administered nasal RT-PCR test, as well as the Ct value. Hellewell et al [5] used the serology testing to obtain a subset of 27 healthcare workers who seroconverted during the study period. To determine the shape of the diagnostic sensitivity curve of the RT-PCR assay (**Fig. S21**), we aim to maximize the log-likelihood

$$L = L_T + L_P$$

where  $L_T$  is the log-likelihood for the time of infection and  $L_P$  is the log-likelihood of the result of the RT-PCR test.

The methodology specified by Hellewell et al [5], accounts for the censoring of symptoms between the testing time to determine the time of infection. Given the date at which they were last asymptomatic ( $t_i^L$ ) and the time of in which they are first symptomatic ( $t_i^F$ ) for the  $N$  individuals, the log-likelihood for the time of infection is

$$L_T = \sum_{i=1}^N \log\left(F(t_i^F - T_i) - F(t_i^L - T_i)\right),$$

where  $F$  is the cumulative distribution of the incubation period specified by Qin et al [6]. We specify the upper bound of the time of infection to be the minimum time of the first positive test, the first day of symptoms, and the first day of a non-zero cycle threshold. The lower bound is assumed to be a month prior to the data-driven upper bound.

For the specified diagnostic sensitivity of the test for all individuals and  $M_i$  tests for individual  $i$ , the likelihood for the test result is expressed as

$$L_P = \sum_{i=1}^N \sum_{j=1}^{M_i} \log\left(s(x_{i,j})^{T_{ij}} (1 - s(x_{i,j}))^{1-T_{ij}}\right),$$

where  $T_{ij}$  indicates the result of test  $j$  for individual  $i$ .

### Temporal diagnostic sensitivity of a rapid antigen test

The diagnostic sensitivity of the rapid antigen test is expressed as the product of the diagnostic sensitivity of the RT-PCR and the percent positive agreement of the rapid antigen test with an RT-PCR test. For the rapid antigen test, we utilized percent positive agreement data for BD Veritor [7]. We model the percent positive agreement at time  $t$  post infection for the rapid antigen test using a linear logistic model

$$\ln\left(\frac{p(t)}{1-p(t)}\right) = \beta_0 + \beta_1 t.$$

We fit the model to the data by maximizing the log-likelihood

$$L = \sum_{i=1}^N \log \left( p(t_i)^{S_i} (1 - p(t_i))^{F_i} \right),$$

where  $S_i$  is the number of successes at time point  $t_i$  and  $F_i$  is the number of failures. We specify that  $\beta_1 < 0$  such that the percent positive agreement declines with respect to time during the optimization. However, the data for the percent positive agreement does not include the temporal dynamics prior to symptom onset. To infer the percent positive agreement during the incubation period, we construct a mapping between the viral load and the percent positive agreement post-symptom onset.

### Vaccination, prevalence and hospitalization

We utilize age specific hospitalization probabilities estimated from the epidemic in France [8] and the age demographics of Europe [9]. We assume that vaccination coverage initiates at the elderly age group ( $\geq 80$ ) and ends in the youngest age group (0–19). The country specific vaccination coverage is that reported for April 12, 2021 [10] Specifying a vaccine coverage of  $v$  (i.e. have received at least one dose), the proportion of the age class vaccinated is

$$v_a = \left( v - \sum_{i=1}^{a-1} n_i \right) / n_a,$$

the proportion to receive the full two doses is

$$v_{a,2} = \left( v_2 - \sum_{i=1}^{a-1} n_i \right) / n_a,$$

and the proportion of the population to receive one dose is  $v_{a,1} = v_a - v_{a,2}$ , where  $n_a$  is the fraction of the population in age class  $a$ .

We utilize age specific vaccine efficacy in the reduction of documented infection ( $\epsilon$ ) and hospitalizations ( $\omega$ ), stratified by dose [11]. Specifying uniform natural immunity across age groups, the proportion of the population that has vaccine acquired immunity to infection is  $\epsilon_1 v_{a,1} (1-r) + \epsilon_2 v_{a,1} (1-r)$ . Using this the level of natural and vaccine-acquired immunity within an age class, the cumulative number of infections over the past  $t$  days within age class  $a$  is

$$\bar{I}_a(t) = \bar{I}_T(t) \cdot w_a \cdot \left( 1 - (1-r) \cdot \left( \epsilon_{a,1} v_{a,1} + \epsilon_{a,2} v_{a,2} \right) - r \right) / \sum_{j=1}^X w_j \cdot \left( 1 - (1-r) \cdot \left( \epsilon_{j,1} v_{j,1} + \epsilon_{j,2} v_{j,2} \right) - r \right),$$



where  $w_a$  is the proportion of the population in age class  $a$ , and  $\bar{I}_T(t)$  is the cumulative number of infections over the past  $t$  days in the whole population. Specifying  $p_{A,a}$  proportion of infections are asymptomatic in age class  $a$ , the prevalence of non-isolated active infections capable of transmission in age class  $a$  is

$$\rho_a = \left( (1 - p_{A,a}) \cdot \bar{I}_a(t_S) + p_{A,a} \cdot \bar{I}_a(t_E) \right) / (w_a \cdot N_T).$$

With incidence data being at the daily time scale and an incubation period of 8.29 days, we specify the age based prevalence of non-isolated cases to be

$$\rho_a = \left( (1 - p_{A,a}) \cdot \bar{I}_a(8) + p_{A,a} \cdot \bar{I}_a(28) \right) / (w_a \cdot N_T).$$

Therefore, the proportion of age class  $a$  who are immune to infection is specified as

$$\varphi_a = (1 - r - \rho_a) \cdot (\varepsilon_{a,1} v_{a,1} + \varepsilon_{a,2} v_{a,2}) + r + \rho_a.$$

Specifying the age specific probability of hospitalization  $h_a$  and uniform proportion of natural immunity, the age specific proportion of infections being hospitalized is

$$\Psi_a = h_a \left( 1 - (1 - r - \rho_a) v_a - r_a - \rho_a + (1 - r - \rho_a) \left( (1 - \varepsilon_{a,1})(1 - \omega_{a,1}) v_{a,1} + (1 - \varepsilon_{a,2})(1 - \omega_{a,2}) v_{a,2} \right) \right) / (1 - \varphi_a)$$

For a specified quarantine strategy, the number of imminent infections in age class is

$$I_a = w_{A,j} \cdot (1 - \varphi_{A,j}) \cdot \sum_{j=1}^N (\lambda_{1,j} + \lambda_{2,j} - \lambda_{3,j} + \lambda_{4,j} + \lambda_{5,j} - \lambda_{6,j}).$$

Thus, the overall number of hospitalizations is

$$H = \sum_{a=1}^A \Psi_a \cdot I_a.$$

Since this number of hospitalization is quantified on an absolute daily scale, we divide by the population size ( $N_T$ ) and multiple by 14 and by 100,000 to obtain the two-week hospitalization rate per 100,000 residents.

### Generalized Approach

For generalized implementation of our modeling framework, we classified a country's status based on the EU traffic-light system, utilizing the age demographics of Europe [9]. Based on the number of new cases in the past 14 days, a

country's risk was stratified into Green (25/100,000), Amber (150/100,000), Red (500/100,000) and Dark Red (1,000/100,000). Given a vaccination coverage in the destination country of travel and risk category of origin country of travel, we computed optimal duration of travel quarantine using the inequality for imminent infections (Eq. 2) with a RT-PCR test on exit from quarantine. To adapt our approach to the limited policy-relevant input currently incorporated into the EU traffic-light system—two-week caseload per capita and percentage of positive tests—we assumed that the vaccination coverage in the origin country is the same as that in the destination country, and specified all parameters other than vaccine coverage and age demographics to be that of the average of the 31 European countries from our country-specific data, so that the population size of the origin country and the destination country were 24.5 million, the population travelling each day was 2452, the average duration of stay was four days,  $r = 0.188$ , such that 18.8% of the destination population possessed natural immunity based on recovery from infection, and 17.6% vaccination coverage.

Daily fractional incidence ( $c$ ) was calculated by averaging over two weeks of daily cases (e.g., (25 cases / 100,000 people) / 14 days). Considering duration of infection was specified to be 28.29 days and assuming a constant daily incidence, the estimated prevalence of non-isolated infections was calculated as  $c(8.29 + 20p_A)$ . To examine the effect of the vaccine coverage on the minimum duration of quarantine, we varied vaccination coverage between 0–100%. We assumed a single vaccine efficacy based on reduction in transmission and reduction in hospitalization from time of initial vaccine to the end of follow-up [11] (**Table S5**) to attain a generalized efficacy for individuals receiving either one dose or two doses, as to consider all scenarios of coverage of a second dose would be computationally intensive.

### Estimating the population abroad

Within the calculation of imminent infections for a specified travel quarantine, we require the number of travellers who are abroad. To obtain these estimates, we utilize the average duration of stay  $d_{AB}$ , the fraction of the total population travelling per day  $m_{AB}$ , and the duration of quarantine for our analysis pertaining to long-term travel quarantine.

The daily number of country-A residents leaving for a long-term visit to country B is  $n_{A,B} = m_{AB} \cdot N_{T,A}$  where  $N_{T,A}$  is the population size of country A and  $m_{AB}$  is the proportion of the total population travelling each day. Since travel is

assumed to be constant and in steady state, the daily number of country-A residents returning for a long-term visit to country B is equal to the daily number of country-A residents leaving for a long-term visit to country B.

The number of residents of country A abroad in country B is  $n_A = m_{AB} \cdot d_{AB} \cdot N_{T,A}$ , whereas the number of non-traveling and non-quarantined country-A residents for a specified quarantine  $q_A$  is  $N_A = N_{T,A}(1 - m_{AB} \cdot (d_{AB} + q_A))$ . We consider only the quarantine duration of the destination country ( $q_A$ ), as the choice of quarantine is independent of the paired countries strategy. Thus, specifying no quarantine for the origin country provides a conservative estimate of the duration of quarantine specified by the destination country.


### Sensitivity analysis

To identify the parameters that have the largest one-way influence on the estimated sufficient duration of travel quarantine, we iteratively altered the value of each parameter by one standard deviation towards the median of the 31 countries while retaining all other parameters fixed. For the age-based parameters—prevalence, vaccine-acquired immunity, natural immunity, and age-demographics—the age-specific values were perturbed by one standard deviation towards the median calculated for the age class. To eliminate the division by zero, the level of immunity was set to 99.9% when the immunity in the age class was 100% or larger after the perturbation. To prevent the population size from adopting negative values due to the perturbation, a  $\log_{10}$  transformation of scale was first conducted on the population size parameter.


### Implementation

We used MATLAB R2019b for the computation and analysis of sufficient travel quarantine durations. When evaluating the inequality for imminent infections, we specified an upper bound error tolerance of  $5 \times 10^{-19}$  to avoid the effects of floating-point precision error in the calculation.

## Supplementary Figures




**Figure S1.** The estimated minimum duration of travel quarantine with an RT-PCR test on exit for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with an RT-PCR test on exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.




**Figure S2.** Sensitivity of sufficient travel quarantine duration to changes in parameters. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence,

prevalence of non-isolated infections, vaccine coverage, seroprevalence, and travel flow, we determine the change in the sufficient duration of travel quarantine with an RT-PCR test on exit when **A**) prevalence in the destination country, **B**) proportion of the population travelling from the destination country to the origin, **C**) proportion of the population travelling from the origin country to the destination, **D**) prevalence in the origin country, **E**) fractional incidence in the destination country, **F**) duration of stay in destination (used in determining population abroad), **G**) natural immunity in origin, **H**) duration of stay in origin (used in determining population abroad), **I**) natural immunity in the destination country, **J**) vaccine immunity in the destination country, **K**) vaccine immunity in the origin country, **L**) age demographics in the destination country, **M**) age demographics in the origin country, **N**) the  $\log_{10}$  population size of the origin country, and **O**) the  $\log_{10}$  population size in the destination country is moved one standard deviation towards the median of the 31 countries while other parameters remained fixed. We included retention of travel ban in our counts of a zero change in travel quarantine. We excluded from our counts the cases where either a travel ban is lifted or added as a result of the perturbation. Ban of travel was lifted in less than 2% of the scenarios for prevalence in the destination, proportion of the population travelling from the origin country to the destination, proportion of the population travelling from the origin country to the destination, fractional incidence in the destination. A switch from implementing quarantine to mandating Ban of travel occurred in less than 3% of the scenarios for proportion of the population travelling from the origin country to the destination, proportion of the population travelling from the origin country to the destination, fractional incidence in the destination, duration of stay in destination, natural immunity in origin, and vaccine immunity in destination. Direction of changes in duration of quarantine are indicated by colour (increased, blue; decreased, orange). Panels are ordered by decreasing standard deviation in the change of quarantine duration (top left). For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.




**Figure S3.** The two-week hospitalization rate per 100,000 residents for a zero-day travel quarantine with an RT-PCR test on exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the two-week hospitalization rate from the estimated imminent infections for a zero-day travel quarantine with an RT-PCR test on exit. Hospitalization rates in the destination country in comparison to rates above (blue), below (orange), or equivalent to (white) the median value were computed across the origin countries. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.




**Figure S4.** The two-week hospitalization rate per 100,000 residents for a zero-day travel quarantine with a rapid antigen test on exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the two-week hospitalization rate from the estimated imminent infections for a zero-day travel quarantine with a rapid antigen test on exit. Hospitalization rates in the destination country in comparison to rates above (blue), below (orange), or equivalent to (white) the median value were computed across the origin countries. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. There was assumed to be no delay in obtaining the rapid antigen test result.







**Figure S5.** The two-week hospitalization rate per 100,000 residents for a zero-day travel quarantine with a rapid antigen test on both entry and exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the two-week hospitalization rate from the estimated imminent infections for a zero-day travel quarantine with a rapid antigen test on entry and exit (i.e. dual test). Hospitalization rates in the destination country in comparison to rates above (blue), below (orange), or equivalent to (white) the median value were computed across the origin countries. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. There was assumed to be no delay in obtaining the rapid antigen test result.




**Figure S6.** The two-week hospitalization rate per 100,000 residents for a zero-day travel quarantine with no testing. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the two-week hospitalization rate from the estimated imminent infections for a zero-day travel quarantine with no test conducted. Hospitalization rates in the destination country in comparison to rates above (blue), below (orange), or equivalent to (white) the median value were computed across the origin countries. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000.




**Figure S7.** The change in the two-week hospitalization rate per 100,000 residents as a result of allowing travel with no testing compared to two-week hospitalization with a travel ban. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the change for two-week hospitalization rate from the estimated imminent infections under a travel ban as a result of allowing travel with a 0-day travel quarantine with no testing. The change in hospitalization rate is stratified by colour (blue = travel decreases the hospitalization rate; red = travel increases the hospitalization rate). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000.




**Figure S8.** The relative decrease in the two-week hospitalization rate per 100,000 residents when extending a zero-day travel quarantine to a 14-day travel quarantine, with an RT-PCR test on exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the relative reduction for two-week hospitalization rate from the estimated imminent infections for extending a zero-day travel quarantine with an RT-PCR test on exit to a 14-day travel quarantine with RT-PCR test on exit. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. For travel quarantine durations of 14 days, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.




**Figure S9.** The relative decrease in the two-week hospitalization rate per 100,000 residents when extending a zero-day travel quarantine to a 14-day travel quarantine, with a rapid antigen test on exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the relative reduction for two-week hospitalization rate from the estimated imminent infections for extending a zero-day travel quarantine with a rapid antigen test on exit to a 14-day travel quarantine with a rapid antigen test on exit. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. There was assumed to be no delay in obtaining the rapid antigen test result.



**Figure S10.** The relative decrease in the two-week hospitalization rate per 100,000 residents when extending a zero-day travel quarantine to a 14-day travel quarantine, with a rapid antigen test on both entry and exit. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the relative reduction for two-week hospitalization rate from the estimated imminent infections for extending a zero-day travel quarantine with a rapid antigen test on entry and exit (i.e. dual testing) to a 14-day travel quarantine with rapid antigen test on entry and exit. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. There was assumed to be no delay in obtaining the rapid antigen test result.




**Figure S11.** The relative decrease in the two-week hospitalization rate per 100,000 residents when extending a zero-day travel quarantine to a 14-day travel quarantine, with no testing conducted. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the relative reduction for two week hospitalization rate from the estimated imminent infections for extending a zero-day travel quarantine with no testing to a 14-day travel quarantine no testing. Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000.




**Figure S12.** The estimated minimum duration of travel quarantine for specified country pairs that reduces imminent infections to be equivalent to border closure when considering variants of concern. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, percentage of variants of concern, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine (colour gradient) that should be stated by the destination country for individuals arriving from the origin country when considering the general transmission and the variant of concern the variants of concern B.1.1.7. and B.1.351. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified quarantine can exceed 14 days). Within- country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result. Please note that the frequency of sampling in some of the countries presented in this Supplementary Figure may not be sufficient enough to adequately assess the level of circulation of the VOCs in the country.







**Figure S13.** The estimated minimum duration of travel quarantine with no testing for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with no test conducted (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000.




**Figure S14.** The estimated minimum duration of travel quarantine with a rapid antigen test on exit for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with a rapid antigen test on exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. We assumed that there was no delay in obtaining the test result from a rapid antigen test.




**Figure S15.** The estimated minimum duration of travel quarantine with a rapid antigen test on entry and exit for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with a rapid antigen test on entry and exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. There was assumed to be no delay in obtaining the test result from a rapid antigen test.




**Figure S16.** Comparison between the country-specific quarantine durations and the durations determined from the EU COVID classification system. The estimates for the minimum quarantine duration are stratified by destination country and origin country (*x* axis) for the country-pair analysis (dots; median dashed line) and our tier-based analysis (solid line) for a quarantine with **A**) a RT-PCR test on exit, **B**) no testing conducted, **C**) rapid antigen test on exit, and **D**) a rapid antigen test on both entry and exit. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result and no delay in obtaining the rapid antigen test. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result.




**Figure S17.** The estimated minimum duration of travel quarantine with a RT-PCR test on exit (parameterized with an alternate diagnostic sensitivity curve) for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with a rapid antigen test on entry and exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result. The alternate diagnostic sensitivity curve for the RT-PCR test is that specified previously by Wells et al [12].



**Figure S18.** The estimated minimum duration of travel quarantine with a rapid antigen test on exit (parameterized by an alternate diagnostic sensitivity curve) for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with a rapid antigen test on exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. We assumed that there was no delay in obtaining the test result from a rapid antigen test. The diagnostic sensitivity of the RT-PCR test, used to determine the diagnostic sensitivity of the rapid antigen test, is that specified previously by Wells et al [12].




**Figure S19.** The estimated minimum duration of travel quarantine with a rapid antigen test on both entry and exit (parameterized by an alternate diagnostic sensitivity curve) for specified country pairs that reduces imminent infections to be equivalent to border closure. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as country-specific demographics, incidence, prevalence of non-isolated infections, vaccine coverage, seroprevalence and travel flow, we determine the minimum duration of travel quarantine with a rapid antigen test on entry and exit (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero-days (white) to no travel (dark purple, i.e., specified travel quarantine can exceed 14 days). Within-country travel quarantine is not evaluated in the analysis (black). Travel flow data was not available for all country pairs (gray). The countries are ranked based on their reported incidence per 100,000 over the last two weeks and stratified based on the European Union country classification system: Green, < 25 cases per 100,000; Amber, 25 to 150 cases per 100,000; Red, 150 to 500 cases per 100,000; and Dark Red, > 500 cases per 100,000. There was assumed to be no delay in obtaining the test result from a rapid antigen test. The diagnostic sensitivity of the RT-PCR test, used to determine the diagnostic sensitivity of the rapid antigen test, is that specified previously by Wells et al [12].



**Figure S20.** The estimated minimum duration of travel quarantine for specified country pairs based on the European Union risk states that reduces imminent infections to be equivalent to border closure for an alternative diagnostic sensitivity curve. Specifying age-dependent vaccine efficacy and proportion of asymptomatic infections, as well as European demographics, 17.6% vaccine coverage, 18.8% natural immunity, we determine the minimum travel duration of quarantine (colour gradient) that should be stated by the destination country for individuals arriving from the origin country. We consider travel quarantine durations of zero days (white) to a travel ban (dark purple, i.e., specified quarantine exceeding 14 days) with **A**) an RT-PCR test on exit, **B**) no test, **C**) a rapid antigen test on exit, and **D**) a rapid antigen test on both entry and exit. For travel quarantine durations of one day or longer, there was a 24-h delay in obtaining the RT-PCR test result and no delay in obtaining the rapid antigen test. For a zero-day travel quarantine, there was assumed to be no delay in obtaining the RT-PCR test result. The diagnostic sensitivity of the RT-PCR test used for this figure is that specified previously by Wells et al [12].





**Figure S21.** The temporal diagnostic sensitivity of a RT-PCR test and rapid antigen test. Specifying an incubation period of 8.29 days (vertical gray dashed line) and a latent period of 2.9 days, the **A**) diagnostic sensitivity of an RT-PCR test (represented by a Hill function; black line) that was fit to the empirical data from Hellewell et al [13], **B**) the estimated percent positive agreement for a rapid antigen test (red line) that was fit to the percent positive agreement data for the BD Veritor rapid antigen test [7] (red dots), **C**) the comparison of the diagnostic sensitivity of the RT-PCR test (black line) and rapid antigen test (red line) using the data from Hellewell et al [13] and **D**) the comparison of the diagnostic sensitivity of the RT-PCR test (black line) and rapid antigen test (red line) using the RT-PCR curve specified by Wells et al [12].

## Supplementary Tables

**Table S1.** References for the construction of the travel flow matrix and duration of stay for the 31 countries

Country	Data source	Year	Reference
Austria	TourMIS; Office for National Statistics (UK)	2019	[14–16]
Belgium	TourMIS; Office for National Statistics (UK)	2019	[14–16]
Bulgaria <sup>a</sup>	TourMIS; Office for National Statistics (UK)	2019	[14–16]
Czechia	TourMIS; Office for National Statistics (UK)	2019	[14–16]
Cyprus	TourMIS; Office for National Statistics (UK)	2018 and 2019	[14–16]
Denmark	Office for National Statistics (UK)	2019	[15,16]
Estonia	TourMIS	2018 and 2019	[14]
Finland	TourMIS; Office for National Statistics (UK)	2019	[14–16]
France	Office for National Statistics (UK); Ministry of Economy for France	2019	[15–17]
Germany	TourMIS; Office for National Statistics (UK)	2019	[14–16]
Greece	Hellenic Statistical Authority; TourMIS ; Office for National Statistics (UK)	2019	[14–16,18,19]
Hungary	TourMIS; Office for National Statistics (UK)	2019	[14–16]
Republic of Ireland	TourMIS; Failte Ireland; Office for National Statistics (UK)	2019	[14–16,20]
Italy	National Institute of Statistics, Italy; TourMIS; Office for National Statistics (UK)	2019	[14–16,21]
Lithuania	Office for National Statistics (UK)	2019	[15,16]
Luxembourg	Office for National Statistics (UK)	2019	[15,16]
Malta	Office for National Statistics (UK)	2019	[15,16]
Netherlands	TourMIS; Office for National Statistics (UK)	2019	[14–16]
Norway <sup>b</sup>	Statistics Norway; TourMIS; Office for National Statistics (UK)	2019 and 2021	[14–16,22,23]
Poland	TourMIS; Office for National Statistics (UK)	2019	[14–16]
Portugal	TourMIS; Office for National Statistics (UK)	2019	[14–16]

Romania	Office for National Statistics (UK)	2019	[15,16]
Russia	Office for National Statistics (UK)	2019	[15,16]
Serbia	Office for National Statistics (UK)	2019	[15,16]
Slovakia	Office for National Statistics (UK)	2019	[15,16]
Slovenia	TourMIS; Office for National Statistics (UK)	2019	[14–16]
Spain	Office for National Statistics (UK)	2019	[15,16]
Sweden	Office for National Statistics (UK)	2019	[15,16]
Switzerland <sup>c</sup>	TourMIS; Office for National Statistics (UK)	2019	[14–16]
United Kingdom	Office for National Statistics (UK)	2019	[15,16]
Turkey <sup>d</sup>	Turkey Statistical Institute; TourMIS; Office for National Statistics (UK)	2019	[14–16,24]

---

<sup>a</sup> Arrivals determined by “Arrivals of visitors at frontiers”, with average duration of stay determined by “Arrivals of visitors at frontiers” and “Bednights in all forms of paid accommodation”

<sup>b</sup> Average duration Norway assumed to be fixed for all countries and based on Jan 2021 travel

<sup>c</sup> Switzerland numbers are based only on arrivals to hotel accommodations, likely underestimating arrivals

<sup>d</sup> Average duration of stay in Turkey is fixed for all countries as there is no country stratified values

**Table S2.** Parameters describing the epidemic profile of the 31 European countries <sup>a</sup>.

Country	Population size	Cases per 100,000 <sup>b</sup>	Prevalence of non-isolated infections per 100,000 <sup>c</sup>	Daily fractional incidence per 100,000	Seroprevalence	Vaccine coverage <sup>d</sup>	Level of vaccine-acquired immunity <sup>e</sup>
Austria	8916185	442	748	21.8	19%	17%	8%
Belgium	11419166	475	818	15.4	20%	17%	7%
Bulgaria	6934625	604	1043	45.0	26%	7%	2%
Cyprus	1313477	536	773	40.2	7%	10%	5%
Czechia	10643487	605	1305	9.3	30%	13%	6%
Denmark	5802733	166	241	8.9	8%	17%	9%
Estonia	1312361	779	1691	20.5	24%	20%	7%
Finland	5534095	106	210	4.1	9%	20%	6%
France	66204315	787	1219	59.1	28%	17%	6%
Germany	84914056	270	414	15.6	11%	16%	7%
Greece	10337172	400	584	15.5	10%	14%	8%
Hungary	9674413	869	1646	52.5	35%	31%	11%
Republic of Ireland	4910357	127	230	7.8	7%	15%	8%
Italy	60313170	389	688	16.2	16%	16%	7%
Lithuania	2794223	444	623	21.8	15%	18%	8%
Luxembourg	618550	454	778	22.3	19%	16%	7%
Malta	439221	165	521	10.7	11%	40%	20%
Netherlands	17156788	598	956	39.2	16%	18%	7%
Norway	5348847	189	345	12.1	4%	16%	8%
Poland	38434445	829	1382	31.3	27%	15%	6%
Portugal	10651263	66	102	2.5	30%	15%	6%
Romania	19237066	354	604	12.1	21%	12%	6%
Russia	146717428	81	136	5.6	16%	6%	3%
Serbia	8746785	625	1138	33.9	18%	20%	12%

Slovakia	5437223	240	479	1.9	25%	16%	6%
Slovenia	2074271	666	1010	13.8	30%	16%	6%
Spain	46021218	219	324	16.8	21%	17%	7%
Sweden	10222546	783	1206	34.0	25%	15%	6%
Switzerland	8775204	304	473	31.3	15%	13%	8%
Turkey	81359693	815	1068	67.1	21%	14%	8%
United Kingdom	67220447	64	139	5.3	18%	48%	18%

<sup>a</sup> The data specified here is for April 12, 2021.

<sup>b</sup> Cases per 100,000 is determined over a two-week period, as specified by the European Union COVID-19 risk stratification

<sup>c</sup> Prevalence of non-isolated infections is a weighted calculation based on the proportion of symptomatic infections and asymptomatic infections, with symptomatic cases isolating on symptom onset. For symptomatic infections, case counts over the last eight days are used to reflect the duration of the incubation period. For asymptomatic infections, case counts used over the last 28 days are used to reflect the duration of disease.

<sup>d</sup> We define vaccination coverage to be the percentage of the population to receive at least one dose of the vaccine

<sup>e</sup> The level of vaccine acquired immunity is dependent on the age-demographics of the country, proportion of the population partially and fully immunizes, as well as age and dose specific vaccine efficacy.

**Table S3.** The percentage of infections that are attributed to the variants of concern B.1.1.7. and B.1.351 [4] <sup>a</sup>

Country	Percentage of cases attributed to VOC B.1.1.7.	Percentage of cases attributed to VOC B.1.351
Austria	0.906	0
Belgium	0.799	0.024
Bulgaria	0	N/A
Cyprus	0	N/A
Czechia	0.825	0
Denmark	0	0
Estonia	0	0
Finland	0	0
France	0.525	0.043
Germany	0.909	0.018
Greece	0	N/A
Hungary	0	N/A
Republic of Ireland	0.809	0.007
Italy	0.893	0.001
Lithuania	0.798	0
Luxembourg	0.658	0.289
Malta	N/A	N/A
Netherlands	0.359	0.009
Norway	0.911	0.089
Poland	0.972	0.003
Portugal	0	0
Romania	0.818	N/A
Russia	0	0
Serbia	0	N/A

Slovakia	0.979	0
Slovenia	0.718	0
Spain	0.769	0.021
Sweden	0.969	0.01
Switzerland	0.946	0.009
Turkey	0.041	0.128
United Kingdom	0.976	0.005

---

<sup>a</sup> These percentages are based on the proportion of cases in the past four weeks based on the data accessed April 23, 2021, which would contain the date of April 12 in Table S2.

**Table S4.** Definitions of the terms in the inequality for daily imminent infection

Imminent infections	Infection term	Age class $j$ infection term	Abbreviation
Due to border closure between country A and country B	$N_T c_A R_A$	$N_T \left( c_A \cdot \frac{w_{Aj}(1-\varphi_{Aj})}{(1-\varphi_A)} \right) \cdot R_{Aj}$	$\lambda_{0,j}$
From residents of country A who are not travelling and are susceptible to infection	$N_A c_A R_A$	$N_A \left( c_A \cdot \frac{w_{Aj}(1-\varphi_{Aj})}{1-\varphi_A} \right) \cdot R_{Aj}$	$\lambda_{1,j}$
From previously susceptible residents of country B who are currently in country A	$n_B c_A \left( \frac{1-\varphi_B}{1-\varphi_A} \right) R_A$	$n_B \cdot \left( c_A \cdot \frac{w_{Bj}(1-\varphi_{Bj})}{1-\varphi_A} \right) \cdot R_{Aj}$	$\lambda_{2,j}$
From infectious residents of country A who are travelling to country B that need to be removed	$n_{A,B} \rho_A R_V$	$n_{A,B} \cdot w_{Aj} \cdot \rho_{Aj} \cdot R_{Vj}$	$\lambda_{3,j}$
From residents of country A who where infected abroad, have gone through quarantine and are returning to country A	$n_{A,B} \rho_B \left( \frac{1-\varphi_A}{1-\varphi_B} \right) R_{Q,A,V}$	$n_{A,B} \cdot w_{Aj} \cdot \rho_{Bj} \left( \frac{1-\varphi_{Aj}}{1-\varphi_{Bj}} \right) \cdot R_{Q,Aj}$	$\lambda_{4,j}$
From infectious residents of country B who are travelling to country A and have gone through quarantine	$n_{B,A} \rho_B R_{Q,A,V}$	$n_{B,A} \cdot w_{Bj} \cdot \rho_{Bj} \cdot R_{Q,Aj}$	$\lambda_{5,j}$
From infectious residents of country B who were infected abroad in country A and are returning to country B that need to be removed	$n_{B,A} \rho_A \left( \frac{1-\varphi_B}{1-\varphi_A} \right) R_V$	$n_{B,A} \cdot w_{Bj} \cdot \rho_{Aj} \left( \frac{1-\varphi_{Bj}}{1-\varphi_{Aj}} \right) \cdot R_{Vj}$	$\lambda_{6,j}$



**Table S5.** Age-specific parameters used in the travel quarantine analysis

Parameter	Age class								Reference
	0–19	20–29	30–39	40–49	50–59	60–69	70–79	≥80	
Percentage of infections asymptomatic	81.91%	77.59%	77.59%	69.46%	69.46%	64.54%	64.54%	35.44%	[25]
Percentage of infections hospitalization	0.1%	0.5%	1.1%	1.4%	2.9%	5.8%	9.3%	26.2%	[8]
Vaccine efficacy (First dose): Transmission <sup>a</sup>	32%	32%	32%	30%	30%	30%	26%	26%	[11]
Vaccine efficacy (Second dose): Transmission <sup>b</sup>	94%	94%	94%	90%	90%	90%	95%	95%	[11]
Vaccine efficacy (First dose): Hospitalization <sup>c</sup>	33%	33%	33%	70%	70%	70%	51%	51%	[11]
Vaccine efficacy (Second dose): Hospitalization <sup>d</sup>	87%	87%	87%	87%	87%	87%	87%	87%	[11]
Vaccine efficacy (General): Transmission <sup>e</sup>	50%	50%	50%	48%	48%	48%	47%	47%	[11]
Vaccine efficacy (General): Hospitalization <sup>f</sup>	50%	50%	50%	74%	74%	74%	57%	57%	[11]

<sup>a</sup> Reduction in documented infection during the time from 0–27 days after first dose

<sup>b</sup> Reduction in documented infection from 7 days after second dose to the end of follow-up

<sup>c</sup> Reduction in hospitalization from 0–27 days after the first dose

<sup>d</sup> Reduction in hospitalization across all age groups from 7 days after second dose to the end of follow-up

<sup>e</sup> Reduction in documented infection from day 0 to the end of follow-up

<sup>f</sup> Reduction in hospitalization from day 0 to the end of follow-up

**Table S6.** Parameter descriptions and values used to determine the minimum duration of travel quarantine

Parameter	Definition	Value	Reference
$t_S$	Incubation period	8.29 days	[6]
$t_L$	Latent period	2.9 days	[26]
$t_E = t_S + 20$	Duration of disease	28.29 days	[27–29]
$R_0$	Basic reproduction number	2.5	[12]
$N$	Population size (EU traffic light analysis)	$24.5 \times 10^6$	The average population size of the 31 countries
$n_{AB}$ and $n_{BA}$	Number of travellers each day (EU traffic light analysis)	2452	Based the average proportion of the total population travelling for the different country pairs
$r$	Natural immunity (EU traffic light analysis)	0.188	The average level of natural immunity among the 31 countries
$d_{AB}$ and $d_{BA}$	Duration of stay to determine proportion abroad (EU traffic light analysis)	4 days	The average duration of stay among the country pairs
$\tau$	Increase in transmission for B.1.1.7 variant of concern	0.82	[1–3]
$\tau$	Increase in transmission for B.1.351 variant of concern	0.50	[3]
$n$	Hill coefficient for the RT-PCR diagnostic sensitivity curve	0.903	Estimated
$K$	Saturation constant for the RT-PCR diagnostic sensitivity curve	0.038	Estimated
$\beta_0$	Logistic regression coefficient for the percent positive agreement curve for the rapid antigen test	5.698	Estimated
$\beta_1$	Logistic regression coefficient for the percent positive agreement curve for the rapid antigen test	-0.379	Estimated

## References

1. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* [Internet]. 2021 Apr 9 [cited 2021 Apr 20];372(6538). Available from: <https://science.sciencemag.org/content/372/6538/eabg3055.abstract>
2. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*. 2021 Mar 25;1–17.
3. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. *N Engl J Med* [Internet]. 2021 Mar 24; Available from: <http://dx.doi.org/10.1056/NEJMc2100362>
4. GISAID - hCov19 Variants [Internet]. [cited 2021 Apr 15]. Available from: <https://www.gisaid.org/hcov19-variants/>
5. Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections [Internet]. 2020 [cited 2021 Jan 13]. Available from: <https://cmmid.github.io/topics/covid19/pcr-positivity-over-time.html>
6. Qin J, You C, Lin Q, Hu T, Yu S, Zhou X-H. Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward follow-up study. *Sci Adv*. 2020 Aug;6(33):eabc1202.
7. Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, et al. Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. *J Clin Microbiol* [Internet]. 2020 Dec 17;59(1). Available from: <http://dx.doi.org/10.1128/JCM.02338-20>
8. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. *Science*. 2020 Jul 10;369(6500):208–11.
9. Population Pyramids of the World from 1950 to 2100 [Internet]. [cited 2021 Apr 20]. Available from: <https://www.populationpyramid.net/europe/2019/>
10. Our World in Data. Data on COVID-19 [Internet]. [cited 2021 Apr 15]. Available from: <https://github.com/owid/covid-19-data>
11. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med* [Internet]. 2021 Feb 24; Available from: <http://dx.doi.org/10.1056/NEJMoa2101765>
12. Wells CR, Townsend JP, Pandey A, Moghadas SM, Krieger G, Singer B, et al. Optimal COVID-19 quarantine and testing strategies. *Nat Commun*. 2021 Jan 7;12(1):356.
13. Hellewell J, Russell TW, The SAFER Investigators and Field Study Team, The Crick COVID-19 Consortium, CMMID COVID-19 working group, Beale R, et al. Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections. *BMC Medicine* [Internet]. 2021 Apr 27;19,(106). Available from: <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-021-01982-x>
14. MODUL University Vienna. City Tourism Recovery Monitor (Total foreign and domestic) [Internet]. TourMIS. [cited 2021 Mar 30]. Available from: [https://www.tourmis.info/index\\_e.html](https://www.tourmis.info/index_e.html)
15. Travel trends estimates: UK residents' visits abroad - Office for National Statistics [Internet]. [cited 2021 Apr 15]. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/leisureandtourism/datasets/ukresidentsvisitsabroad>

16. Travel trends estimates: overseas residents in the UK - Office for National Statistics [Internet]. [cited 2021 Apr 15]. Available from:  
<https://www.ons.gov.uk/peoplepopulationandcommunity/leisureandtourism/datasets/overseasresidentsvisiststotheuk>
17. ÉTUDES ÉCONOMIQUES. 87 million foreign tourists in France in 2017 [Internet]. 2018 [cited 2021 Apr 21]. Available from:  
[https://www.entreprises.gouv.fr/files/files/directions\\_services/etudes-et-statistiques/4p-DGE/2018-07-4p-N84-EVE-version-anglaise.pdf](https://www.entreprises.gouv.fr/files/files/directions_services/etudes-et-statistiques/4p-DGE/2018-07-4p-N84-EVE-version-anglaise.pdf)
18. Greece in Figures - ELSTAT. Arrivals and nights spent in hotels, similar establishments and tourist campsites by Region and by country of residence [Internet]. 2019 [cited 2021 Apr 15]. Available from:  
[https://www.statistics.gr/en/greece-in-figures?p\\_p\\_id=com\\_liferay\\_portal\\_search\\_web\\_portlet\\_SearchPortlet\\_INSTANCE\\_3&p\\_p\\_lifecycle=0&p\\_p\\_state=maximized&p\\_p\\_mode=view&\\_com\\_liferay\\_portal\\_search\\_web\\_portlet\\_SearchPortlet\\_INSTANCE\\_3\\_mvcPath=%2Fview\\_content.jsp&\\_com\\_liferay\\_portal\\_search\\_web\\_portlet\\_SearchPortlet\\_INSTANCE\\_3\\_assetEntryId=17069628&\\_com\\_liferay\\_portal\\_search\\_web\\_portlet\\_SearchPortlet\\_INSTANCE\\_3\\_type=document](https://www.statistics.gr/en/greece-in-figures?p_p_id=com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_mvcPath=%2Fview_content.jsp&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_assetEntryId=17069628&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_type=document)
19. Greece in Figures - ELSTAT. Arrivals and nights spent in hotels, similar establishments and tourist campsites (Final Data) [Internet]. [cited 2021 Apr 15]. Available from:  
[https://www.statistics.gr/en/greece-in-figures?p\\_p\\_id=com\\_liferay\\_portal\\_search\\_web\\_portlet\\_SearchPortlet\\_INSTANCE\\_3&p\\_p\\_lifecycle=0&p\\_p\\_state=maximized&p\\_p\\_mode=view&\\_com\\_liferay\\_portal\\_search\\_web\\_portlet\\_SearchPortlet\\_INSTANCE\\_3\\_mvcPath=%2Fview\\_content.jsp&\\_com\\_liferay\\_portal\\_search\\_web\\_portlet\\_SearchPortlet\\_INSTANCE\\_3\\_assetEntryId=17020463&\\_com\\_liferay\\_portal\\_search\\_web\\_portlet\\_SearchPortlet\\_INSTANCE\\_3\\_type=document](https://www.statistics.gr/en/greece-in-figures?p_p_id=com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_mvcPath=%2Fview_content.jsp&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_assetEntryId=17020463&_com_liferay_portal_search_web_portlet_SearchPortlet_INSTANCE_3_type=document)
20. Key Tourism Facts 2019 [Internet]. Failte Ireland. 2021 [cited 2021 Apr 21]. Available from:  
[https://www.failteireland.ie/FailteIreland/media/WebsiteStructure/Documents/3\\_Research\\_Insights/4\\_Visitor\\_Insights/KeyTourismFacts\\_2019.pdf?ext=.pdf](https://www.failteireland.ie/FailteIreland/media/WebsiteStructure/Documents/3_Research_Insights/4_Visitor_Insights/KeyTourismFacts_2019.pdf?ext=.pdf)
21. OECD. Istat Statistics [Internet]. [cited 2021 Apr 21]. Available from: <http://dati.istat.it/?lang=en>
22. Norway S. 08401: Accommodation establishments total. Guest nights, by guests' country of residence (C) (closed series) 2005M01 - 2019M12 [Internet]. StatBank. [cited 2021 Apr 21]. Available from:  
<https://www.ssb.no/en/statbank/table/08401/>
23. Statistics Norway. Accommodation: guest nights at commercial and non-commercial establishments [Internet]. [cited 2021 Apr 21]. Available from: <https://www.ssb.no/en/transport-og-reiseliv/reiseliv/statistikk/overnattingar>
24. Tourism Statistics, 4th Quarter: October-December and Annual, 2020 [Internet]. TURKSTAT. [cited 2021 Apr 13]. Available from:  
<https://data.tuik.gov.tr/Bulten/Index?p=Tourism-Statistics-Quarter-IV:-October-December-and-Annual,-2020-37438>
25. Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Sabatino G, et al. Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy. *JAMA Netw Open*. 2021 Mar 1;4(3):e211085–e211085.
26. Wang X, Pasco RF, Du Z, Petty M, Fox SJ, Galvani AP, et al. Impact of Social Distancing Measures on Coronavirus Disease Healthcare Demand, Central Texas, USA. *Emerg Infect Dis*. 2020 Oct;26(10):2361–9.
27. Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. Dynamic Profile of RT-PCR Findings from 301 COVID-19 Patients in Wuhan, China: A Descriptive Study [Internet]. *SSRN Electronic Journal*. Available from:  
<http://dx.doi.org/10.2139/ssrn.3548769>

28. CDC. Interim Guidance on Duration of Isolation and Precautions for Adults with COVID-19 [Internet]. 2021 [cited 2021 Apr 13]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>
29. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe*. 2021 Jan;2(1):e13–22.